Doug represented a Fortune 50 pharmaceutical company in antitrust litigation against a competitor, suing over an allegedly illegal tying arrangement involving the two companies’ oncology chemotherapy adjunct drugs. We acted as local counsel with a major New York firm. The matter involved a state-of-the-art preliminary injunction trial in federal court in New Jersey, and eventually settled for $200 million.
These cookies are essential for the website to function and cannot be switched off.
These cookies help us understand how visitors interact with the website by collecting information anonymously.
These cookies allow the website to remember choices you make to give you better functionality.
These cookies are used to track visitors across websites to display relevant advertising.